Tango Therapeutics TNGX Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's unrealized losses on investments (before tax)?
- Tango Therapeutics (TNGX) reported unrealized losses on investments (before tax) of $134K in Q1 2026.
- How has Tango Therapeutics's unrealized losses on investments (before tax) changed year-over-year?
- Tango Therapeutics's unrealized losses on investments (before tax) increased by 396.3% year-over-year, from $27K to $134K.
- What is the long-term trend for Tango Therapeutics's unrealized losses on investments (before tax)?
- Over 4 years (2021 to 2025), Tango Therapeutics's unrealized losses on investments (before tax) has grown at a -100.0% compound annual growth rate (CAGR), from $766K to $0.